All In Biotech

Drug Trial Radar · NCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

787

Planned (sponsor's estimate)

Start

May 20, 2025

Primary completion

May 2030

Study completion Dec 2032

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Conditions

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma

Interventions

  • PirtobrutinibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with a Grade ≥3 treatment-emergent AEsTime frame: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • Cancer Specialists, LLC

    Jacksonville, Florida · Not yet recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • The Emory Clinic

    Atlanta, Georgia · Not yet recruiting

  • Northwestern University

    Chicago, Illinois · Not yet recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic- Minnesota

    Rochester, Minnesota · Recruiting

  • University Of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Cayuga Cancer Center

    Ithaca, New York · Recruiting

  • Northwell Health

    Lake Success, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York · Not yet recruiting

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York · Not yet recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Flinders Medical Centre

    Adelaide, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • Linear Clinical Research

    Victoria, Australia · Recruiting

  • CHU de Nantes - Hotel Dieu

    Nantes, France · Recruiting

  • IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi

    Bologna, Italy · Recruiting

  • Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Nagoya Medical Center

    Aichi-Ken, Japan · Recruiting

  • National Cancer Center Hospital

    Cho-ku, Japan · Recruiting

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan · Recruiting

  • Tokai University Hospital- Isehara Campus

    Isehara, Japan · Recruiting

  • Tohoku University Hospital

    Miyagi-Ken, Japan · Recruiting

  • Hokkaido University Hospital

    Sapporo, Japan · Recruiting

  • Pratia MCM Krakow

    Krakow, Poland · Recruiting

  • Instytut Hermatologii I Transfuzjologii

    Warsaw, Poland · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • St James's University Hospital

    Leeds, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Not yet recruiting

  • Derriford Hospital

    Plymouth, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.